Tumor Responses with Crizotinib in MET-Amplified Disease Help Define a New Targetable Form of Lung Cancer
June 2, 2014 · Comments Off
A study presented at the American Society of Clinical Oncology (ASCO) Annual Meeting 2014 reports the results of a first-in-human, phase 1 dose escalation trial of crizotinib (XALKORI) in 14 patients with advanced, MET-amplified non-small cell lung cancer (NCT00585195).
Results in Phase I Trial of OMP-54F28, a Wnt Inhibitor Targeting Cancer Stem Cells
May 31, 2014 · Comments Off
Phase 1 clinical trial results presented at ASCO 2014 pave way for cancer stem cell drug, OMP-54F28, in new clinical trials for pancreatic, ovarian, and hepatocellular cancers.
A study presented at the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO) describes the results of a phase I clinical trial of the investigational agent DMOT4039A against pancreatic and ovarian cancers. In this early clinical trial with the goal of identifying possible risks and defining likely dosages, the drug was well tolerated and in some patients showed initial evidence of anti-cancer activity.
After Great Dane success, cancer doc eyes brain tumors
June 27, 2013 · Comments Off
Two University of Colorado Cancer Center publications set stage for K9 cancer vaccine test with human glioblastoma -- after the dramatic and prolonged improvement of Dr. Michael Graner's dog, Star, trial of cancer vaccine may move into human trial
AACR News: Rigosertib Phase 1 results lead to disease-focused Phase 2 development
April 9, 2013 · Comments Off
Results of a phase 1 clinical trial reported at the American Association for Cancer Research (AACR) annual conference show that orally administered Rigosertib is well tolerated in patients with advanced solid tumors. This is the first trial in which orally administered Rigosertib, a dual kinase inhibitor, was studied in solid tumors. Intravenously rigosertib is already in phase 3 clinical trials for myelodysplastic syndrome and pancreatic cancer and oral rigosertib is being studied in a pair of Phase II trials in lower-risk transfusion dependent MDS patients. The drug candidate is being developed by Onconova Therapeutics, Inc., of Pennington, NJ.
Clinical trial hits new target in war on breast cancer
December 3, 2012 · Comments Off
KEY POINTS: In addition to estrogen, progesterone and HER2, androgen drives breast cancer The drug...
Enzalutamide adds five months survival in late-stage prostate cancer
August 16, 2012 · Comments Off
Results of a phase III clinical trial of the drug Enzalutamide, published yesterday in the...
New clinical trial design promises to accelerate cancer drug approvals
June 12, 2012 · Comments Off
KEY POINTS: Cancer drug development can cost millions and take years New FDA regulations based...
NTRK1: a new oncogene and target in lung cancer
June 12, 2012
Wings of Hope to benefit pancreatic cancer research at CU Cancer Center
September 16, 2014 · No comments
A Teal Saturday: Gynecologic Cancer Symposium at CU
September 15, 2014 · No comments
amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno ASCO biomarkers bladder cancer breast cancer cancer cancer grants cancer research colorado cancer stem cells Cancer Survivorship clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma microRNA ovarian cancer Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge skin cancer Thomas Flaig tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
“Sandy is interested in leaving a legacy of innovation to ensure that the University of Colorado has the... fb.me/3APlBMaNV
Great news! fb.me/2rRNa1u1A
A collaborative study between researchers at the University of Colorado Cancer Center and the National Cancer... fb.me/3ESuyGbqF
Collaboration between CU Cancer Center and NantBioScience will allow Theodorescu and team to work toward drugs... fb.me/3vrD9ACDf